For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Follistatin 344
Illustration for Follistatin 344

THE PEPSRADAR ENCYCLOPEDIA

Follistatin 344

Myostatin-pathway and muscular-dystrophy research

Research topics · Sources checked 2026-10-04

Read the studies ↓

Follistatin 344 · KEY FACTS

Content updated · how dates work

Saved peptides

What is Follistatin 344?

Follistatin 344 refers to a follistatin precursor isoform. A frequently cited human study delivered an FS344 gene construct using a viral vector; it did not test injections of a supplier’s follistatin protein.

Biological role or research focus

Myostatin-pathway and muscular-dystrophy research.

The lack of a concurrent control limits causal interpretation. Gene-delivery outcomes cannot be transferred to a protein vial, and six participants cannot exclude uncommon harms.

Role reference: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Names you may encounter

FS344 · FST344 · FLGR242

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Follistatin precursor isoform used in gene-therapy research
Research focus
Myostatin-pathway and muscular-dystrophy research
Featured evidence
Related intervention · Human uncontrolled gene-therapy study
Source check
October 4, 2026

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Quick answers

Is Follistatin 344 FDA approved?
No. No FDA-approved drug contains Follistatin 344. Source ↗
Is Follistatin 344 safe?
Follistatin-344 protein has never been safety-tested in people. A case series linked self-injected products to fluid under the retina, and tested black-market products often did not match their labels. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is Follistatin 344 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S4.3 Agents preventing activin receptor IIB activation). Source ↗
Has the FDA taken action over Follistatin 344?
Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Follistatin among bulk substances that are not eligible for 503A compounding exemptions. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research1 Related compound / review1 Other evidence
StudyTypePopulation / model
FS344 gene therapy in Becker muscular dystrophy (2015)Related intervention · Human uncontrolled gene-therapy studySix men with Becker muscular dystrophy.
Follistatin-344 listings · eye-harm signal (2020)Human retrospective case series11 male bodybuilding athletes seen at one clinic with reduced vision after injections labeled follistatin-344.
Follistatin-344 · product identity testing (2019)Analytical product study17 black-market products sold as follistatin formulations.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Related intervention · Human uncontrolled gene-therapy study · 2015

FS344 gene therapy in Becker muscular dystrophy

What did this publication test, and what did it find?

Population / model
Six men with Becker muscular dystrophy.
Study design
Uncontrolled phase 1/2a study of intramuscular AAV1.CMV.FS344 gene delivery.
Main finding
Four participants improved their six-minute-walk distance, while two showed no improvement. No adverse effects were reported in this small study.
Limits & context
The lack of a concurrent control limits causal interpretation. Gene-delivery outcomes cannot be transferred to a protein vial, and six participants cannot exclude uncommon harms.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Human retrospective case series · 2020

Follistatin-344 listings · eye-harm signal

What safety signal has been reported after self-administration?

Population / model
11 male bodybuilding athletes seen at one clinic with reduced vision after injections labeled follistatin-344.
Study design
Retrospective clinical records and retinal imaging; no comparison group.
Main finding
Central serous chorioretinopathy was identified. Fluid resolved after an average 2.3 months in eight single-exposure cases; three multiple-exposure cases had recurrence.
How to read it
This is an association and a reason to investigate, not a controlled estimate of causal risk.
Limits & context
Referral selection, lack of a denominator, possible confounding, and uncertain product identity prevent estimating incidence or proving causation. It supplies no evidence of muscle-building efficacy.

Source: Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. ↗

Analytical product study · 2019

Follistatin-344 · product identity testing

Did the tested products contain what their labels claimed?

Population / model
17 black-market products sold as follistatin formulations.
Study design
Protein detection methods using purification, electrophoresis, and immunoblotting.
Main finding
Nine products contained follistatin; others included growth-promoting peptides. The nine positive products contained His-tagged FS344 with substantial oligomers.
How to read it
A supplier label is not confirmation of protein identity, purity, or clinical equivalence.
Limits & context
This small historical sample is not a current supplier ranking or market-wide prevalence estimate. Detection does not demonstrate safety or effectiveness. A linked published erratum should also be consulted.

Source: Detection of black market follistatin 344. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming Follistatin 344 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 2 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. ↗
Sports medicine (Auckland, N.Z.) · 2026 Aug · Journal Article, Review

Detection of black market follistatin 344. ↗
Drug testing and analysis · 2020 Oct · Published Erratum

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Follistatin-344 protein has never been safety-tested in people. A case series linked self-injected products to fluid under the retina, and tested black-market products often did not match their labels.

Human safety data: None

No human safety studies of follistatin-344 protein products exist. A six-person gene-therapy study in Becker muscular dystrophy reported no adverse effects, but gene delivery is a different intervention with a different risk profile.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • Central serous chorioretinopathy (fluid under the retina, blurred vision) in 11 bodybuilders after self-injection; it recurred in three with repeated use
  • Black-market products tested did not reliably contain the labeled protein; some contained other growth-promoting peptides

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Central serous chorioretinopathy with follistatin-344: case series (2020) ↗ · Detection of black market follistatin 344 (2019) ↗ · Follistatin gene therapy trial in Becker muscular dystrophy (2015) ↗

Safety & what remains unknown

A viral-vector intervention has a different safety profile from protein administration. The study does not establish a safe consumer use.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Evidence boundaries

The lack of a concurrent control limits causal interpretation. Gene-delivery outcomes cannot be transferred to a protein vial, and six participants cannot exclude uncommon harms.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S4.3 Agents preventing activin receptor IIB activation
Named explicitly ("follistatin") as a myostatin-binding protein. source

FDA actions

  • FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Follistatin among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

The featured study concerns a proof-of-principle muscular-dystrophy intervention. It does not validate bodybuilding products labeled Follistatin 344.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

Follistatin antagonizes members of the activin/myostatin signaling system. Expressing a gene construct in muscle is a different intervention from administering a purified protein preparation.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Questions worth asking

  • Was the human trial an injection of Follistatin 344 protein?
  • What material, population, and route were actually studied?
  • The lack of a concurrent control limits causal interpretation. Gene-delivery outcomes cannot be transferred to a protein vial, and six participants cannot exclude uncommon harms.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Was the human trial an injection of Follistatin 344 protein?

No. It delivered an FS344 gene construct using an adeno-associated viral vector. That distinction is central to interpreting the result.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. · 2015 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections